2Dombret H, Raffoux E, Gardin C. Acute myeloid leukemiain the elderly [J]. Semin Oncol, 2008, 35 (4).:430438.
3Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloidleukaemiain the elderly: a review [J]. Br J Haematol, 2011,152 (5).: 524-542.
4Farag SS, Archer KJ, Mrozek K, et al. Pretreatmentcytogenetics add to other prognostic factors predicting completeremission and long-term outcome in patients 60 years of age orolder with acute myeloid leukemia: results from Cancer andLeukemia Group B 8461 [S]. Blood, 2006, 108 (1).: 63-73.
5Leith CP, KopeckyKJ, ChenIM, eta!. Frequency and clinicalsignificance of the expression of the multidrug resistance prote-ins MDRl/P-glycoprotein, MRP1, and LRP in acute myeloidleukemia: a Southwest Oncology Group Study [J]. Blood,1999,94 (3).: 1086-1099.
6MenzinJ, LangK, Earle CC, etal. The outcomes and costsof acute myeloid leukemia among the elderly [J]. Arch InternMed, 2002, 162 (14).: 1597-1603.
7Pautas C, Merabet F, Thomas X,et al. Randomized studyof intensi ed anthracycline doses for induction and recombinantinterleukin-2 for maintenance in patients with acute myeloid leu-kemia age 50 to 70 years: results of the ALFA-9801 study [J].J Clin Oncol, 2010,28 (5).: 808-814.
8Schlenk RF, Frohling S, Hartmann F, etal. Phase III studyof all-trans retinoic acid in previously untreated patients 61 yearsor older with acute myeloid leukemia [J]. Leukemia, 2004,18 (11).: 1798-1803.
9Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia[J]. N Engl J Med, 2009, 361 (13).: 1235-1248.
10Castaigne S, Pautas C, Terre C, etal. Effect of gemtuzumabozogamicin on survival of adult patients with de novo acute my-eloid leukaemia (ALFA-0701).:阻 randomised, open-label,phase 3 study [J]. Lancet, 2012,379 (9825).: 1508-1516.
